We all do know that being a cancer survivor means that you are at an increased risk to suffer serious psychological distress such as anxiety and depression The surprise is that this increased susceptibility can extend even a decade after the treatment ends. Survivors who are diagnosed in their younger years, unmarried, had less than [...]
Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan has released some very significant survival data about a previously reported, double-blind, randomized, multicenter phase 3 trial. This trial compared combined androgen blockade [...]
There was just a release of some of the data from the on-going review sipuleucel-T, or Provenge, in men with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic prostate cancer. The data wes presented by Oregon Health & Realm University Cancer [...]
There was an interesting study done at the Department of Primary Care, Höglandssjukhuset, Nässjö, Sweden and the Department of Urology, Sahlgrenska University Hospital/SU Sahlgrenska, Gothenburg, Sweden. The study attempted to understand how men who are newly diagnosed with advanced prostate cancer are affected by fatigue before the side effects of any treatment has an impact [...]
Men with metastatic hormone-refractory prostate cancer (mHRPC) who become docetaxel-refractory (no longer responsive to docetaxel therapy have no approved second line chemotherapy available. One could say that they have reached the proverbial brick wall. Where to go and what to do is not at all clear. Most of us do not want to just roll [...]